Development of chitosan nanoparticles as drug delivery system for a prototype capsid inhibitor

M Xue, S Hu, Y Lu, Y Zhang, X Jiang, S An… - International Journal of …, 2015 - Elsevier
Oral delivery of biopharmaceutics drug disposition classification system (BDDCS) Class II or
IV drugs with poor aqueous solubility and poor enzymatic and/or metabolic stability is very …
被引用次数：59 相关文章

Development of chitosan nanoparticles as drug delivery system for a prototype capsid inhibitor

M Xue, S Hu, Y Lu, Y Zhang, X Jiang, S An… - International Journal of …, 2015 - infona.pl
Oral delivery of biopharmaceutics drug disposition classification system (BDDCS) Class II or
IV drugs with poor aqueous solubility and poor enzymatic and/or metabolic stability is very …

Development of chitosan nanoparticles as drug delivery system for a prototype capsid inhibitor

M Xue, S Hu, Y Lu, Y Zhang, X Jiang, S An… - International Journal of …, 2015 - hero.epa.gov
Oral delivery of biopharmaceutics drug disposition classification system (BDDCS) Class II or
IV drugs with poor aqueous solubility and poor enzymatic and/or metabolic stability is very …

Development of chitosan nanoparticles as drug delivery system for a prototype capsid inhibitor.

M Xue, S Hu, Y Lu, Y Zhang, X Jiang, S An… - International Journal …, 2015 - europepmc.org
Oral delivery of biopharmaceutics drug disposition classification system (BDDCS) Class II or
IV drugs with poor aqueous solubility and poor enzymatic and/or metabolic stability is very …

Development of chitosan nanoparticles as drug delivery system for a prototype capsid inhibitor

M Xue, S Hu, Y Lu, Y Zhang, X Jiang… - International …, 2015 - pubmed.ncbi.nlm.nih.gov
Oral delivery of biopharmaceutics drug disposition classification system (BDDCS) Class II or
IV drugs with poor aqueous solubility and poor enzymatic and/or metabolic stability is very …